Akari Therapeutics (AKTX) Competitors $1.12 -0.02 (-1.75%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. CGEN, ALEC, GALT, ACOG, IKT, ALTS, KYTX, RAPT, LXEO, and BDTXShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), ALT5 Sigma (ALTS), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), Lexeo Therapeutics (LXEO), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Compugen Alector Galectin Therapeutics Alpha Cognition Inhibikase Therapeutics ALT5 Sigma Kyverna Therapeutics Rapt Therapeutics Lexeo Therapeutics Black Diamond Therapeutics Compugen (NASDAQ:CGEN) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Do institutionals and insiders have more ownership in CGEN or AKTX? 12.2% of Compugen shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer CGEN or AKTX? In the previous week, Akari Therapeutics had 1 more articles in the media than Compugen. MarketBeat recorded 2 mentions for Akari Therapeutics and 1 mentions for Compugen. Akari Therapeutics' average media sentiment score of 0.13 beat Compugen's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Compugen Neutral Akari Therapeutics Neutral Which has more risk and volatility, CGEN or AKTX? Compugen has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Which has higher earnings and valuation, CGEN or AKTX? Compugen has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M5.21-$14.23M-$0.16-10.16Akari TherapeuticsN/AN/A-$19.79MN/AN/A Is CGEN or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Compugen's net margin of -51.27%. Compugen's return on equity of -24.51% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen-51.27% -24.51% -12.19% Akari Therapeutics N/A -213.59%-65.60% Do analysts recommend CGEN or AKTX? Compugen presently has a consensus price target of $4.00, suggesting a potential upside of 146.15%. Given Compugen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Compugen is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCompugen beats Akari Therapeutics on 9 of the 13 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.07M$2.93B$5.49B$9.01BDividend YieldN/A2.43%5.25%4.03%P/E RatioN/A20.7927.1520.02Price / SalesN/A180.75375.3079.54Price / CashN/A42.7337.5058.41Price / Book1.347.668.015.52Net Income-$19.79M-$55.05M$3.17B$248.51M7 Day Performance-4.66%8.58%4.06%5.10%1 Month Performance-8.16%5.44%4.03%7.49%1 Year Performance-68.14%2.42%30.13%18.08% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics1.5444 of 5 stars$1.13-1.7%N/A-66.1%$36.07MN/A0.009CGENCompugen1.4683 of 5 stars$1.78+7.2%$4.00+124.7%-1.7%$148.13M$27.86M-11.1370Positive NewsALECAlector4.1099 of 5 stars$1.40-5.4%$4.00+185.7%-65.7%$147.99M$100.56M-1.11270GALTGalectin Therapeutics1.6086 of 5 stars$2.11-9.4%$6.00+184.4%+4.7%$147.47MN/A-2.939Positive NewsACOGAlpha Cognition1.5511 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/AIKTInhibikase Therapeutics1.3101 of 5 stars$1.95+20.4%$6.50+233.3%+52.7%$144.97M$260K-0.736ALTSALT5 Sigma0.0662 of 5 stars$7.24-10.9%N/AN/A$141.91M$12.53M0.00170KYTXKyverna Therapeutics2.5248 of 5 stars$3.07-6.4%$18.50+502.6%-57.8%$141.76M$7.03M-0.9196News CoveragePositive NewsRAPTRapt Therapeutics4.4197 of 5 stars$8.00-5.1%$24.00+200.0%-67.9%$139.40M$1.53M-0.4280Analyst ForecastLXEOLexeo Therapeutics2.482 of 5 stars$4.02-2.4%$16.60+312.9%-72.1%$136.77M$650K-1.2258BDTXBlack Diamond Therapeutics2.7586 of 5 stars$2.48+5.5%$14.60+488.7%-46.6%$133.63MN/A41.3390News Coverage Related Companies and Tools Related Companies Compugen Competitors Alector Competitors Galectin Therapeutics Competitors Alpha Cognition Competitors Inhibikase Therapeutics Competitors ALT5 Sigma Competitors Kyverna Therapeutics Competitors Rapt Therapeutics Competitors Lexeo Therapeutics Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
